[Statistic correlation of carcinoembryonal antigen (CEA), alpha-feto protein (AFP) and isoenzymes of mitochondrial and BB creatine phosphokinase (CK+-BB and CK-MT) in patients with neoplasms]. / Correlazione statistica tra antigene carcinoembrionale (CEA), alfa-feto proteina (AFP) e isoenzimi della creatinfosfochinasi BB e mitocondriale (CK-BB e CK-MT) nei pazienti portatori di neoplasie.

In this work we have considered CK isoenzymes (CKBB-CKMT) as tumoral markers. The statistical comparison of the results (x2) executed on thirty neoplastic patients selected at random, has proved that CKBB and/or CKMT frequency is the same as the CEA one (CEA vs BB = N.S.; CEA VS MT = N.S.; CEA VS BB + MT = N.S.) and higher than AFP one (AFP VS BB = P less than 0.001; AFP VS MT = P less than 0.01). The isoenzymes' determination was executed by electrophoretic method (Helena) which is sensitive, specific and swift.

[Statistical analysis of variations in total cholesterol, HDL, HDL2, HDL3, LDL-cholesterol, VLDL-triglycerides, apo-A and apo-B lipoproteins in dyslipidemias during antilipemic therapy]. / Analisi statistica delle variazioni del colesterolo totale, HDL, HDL2, HDL3, LDL-colesterolo, VLDL-trigliceridi, apo-A e apo-B lipoproteine nelle dislipidemie in trattamento antilipemico.

In our study, bezafibrate in short-acting formula and long-acting formula, administered to hyperlipidaemic patients, resulted in a significant lowering of atherogenic lipids and lipoproteins (chol.-T, LDL and VLDL-chol., apolipoprotein B and VDLD-TR), and a marked increase in the levels of HDL, HDL2, HDL3-chol. and apolipoprotein A with a protective action as regards vascular atherosclerotic damage. The long-acting formula showed a greater effectiveness.

[Behavior of blood values of prolactin, TSH, FSH, and LH in gastroduodenal ulcer during drug therapy]. / Osservazioni sul comportamento dei valori ematici di PRL, TSH, FSH, LH NELLA malattia ulcerosa gastro-duodenale in trattamento farmacologico.

A study has been carried out on 20 male patients affected by gastric and duodenal ulcer disease and undergoing pharmacological treatment with pirenzepine, cimetidine, carbenoxolone and zolimidine in a multicentre controlled clinical trial, on PRL, TSH, FSH, LH plasma levels, taking into account the circadian rhythms of these endocrine variables. Basal and follow-up tests have been carried out, as well as a stimulation tests with TRH and LHRH. The findings do not allow for definite conclusions: two patients have shown moderate increases in the PRL levels after cimetidine; all patients have shown optimum responses to the stimulation test.

[Correlations of cardiodynamic parameters and the adrenergic system in essential arterial hypertension at rest and during exertion]. / Analisi delle correlazioni tra parametri cardiodinamici e sistema adrenergico nella ipertensione arteriosa essenziale a riposo e dopo sforzo.

The study of hemodynamic and humoral changes stressed the possibility--statistically significant for the values of end diastolic volume (EDV), ejection fraction (EF), end systolic volume (ESV), dopamine (DA), norepinephrine (NE)-to point out the differences between normotensive and hypertensive subjects in the pre-clinic stage during exercise test, and to predict their evolution along with the relative diagnostic, therapeutic and prognostic corollaries.

Effectiveness of ibopamine in the management of ascitic liver cirrhosis--a controlled study v placebo and frusemide.

1 Thirty in-patients of both sexes suffering from ascitic liver cirrhosis were divided into three groups treated with (a) a placebo, (b) ibopamine (SB 7505, a new oral dopaminergic drug) and (c) frusemide, for 10 days. 2 Body weight decreased with both frusemide and ibopamine, diuresis and urinary excretion of Na+ and Cl- increased with both drugs; whereas urinary excretion of K+ increased only with frusemide. 3 An important difference between the frusemide and ibopamine treatment was encountered in creatinine clearance, which increased only with ibopamine, and in blood uric acid which increased only with frusemide. 4 The antidiuretic hormone (ADH) in the plasma of cirrhotic patients was lower than the sensitivity limit of the radioimmunoassay method, whereas in a group of healthy subjects it could be clearly measured. 5 The treatments did not affect systolic or diastolic blood pressure, heart rate, or a series of haematochemical parameters. 6 The increase in diuresis and creatinine clearance and the very good tolerability encountered with ibopamine highlight this new oral dopamine agonist as a useful drug in the management of liver cirrhosis.

Papaverine bioavailability in delayed absorption formulations.

The bioavailability of non "normal-acting" and three "delayed" papaverine formulations was compared in twenty hospitalized human subjects. Papaverine was evaluated in the blood at the nanogram level by a highly sensitive, specific gas chromatographic method with electron capture detection. Only one of the three chronoid preparations had appropriately delayed bioavailability 89% in comparison to normal acting formulation.

Renal effect of SB 7505: a double-blind study.

Two groups of 20 patients with no evidence of cardiovascular, hepatic, renal or gastrointestinal failure were treated orally for five days with placebo or SB 7505 100 mg/day. No change was observed in heart rate or blood pressure. Urine output, the excretion of Na, K and Cl, and creatinine clearance were significantly increased.

Clinical tolerability of ibopamine hydrochloride (SB 7505).

The clinical tolerance of ibopamine hydrochloride (Sb 7505) was investigated in 12 volunteers. The drug was administered on alternate days (2nd, 4th, 6th, 8th, 10th, 12th), starting at 100 mg and increasing by 50 mg each time to reach 350 mg on the 12th day. On the other days (1st, 3rd, 5th, 7th, 9th, 11th and 13th) a placebo was given. Diuresis increased progressively with the dose, reaching a maximum increase of 88% after the last dose, and showing a small residual effect on each subsequent placebo day. Body weight showed a marginal change and decreased by 2% in the last two days of treatment. Heart rate, systolic, diastolic and mean blood pressure showed only marginal fluctuations of about 7% around the mean values, which were of little statistical and of no clinical significance. Haematological and biochemical parameters were not affected. No side effect was noticed. The dose of 350 mg may probably be increased without leading to side effects.

Acute clinical tolerance of creatinol O-phosphate.

Acute clinical tolerance to N-methyl-N-(beta-hydroxyethyl) guanidine O-phosphate (creatinol O-phosphate, COP) was investigated in volunteer human subjects without heart or renal disease and without other serious illness. COP was administered i.v. at three different dosages, 1020 mg (group A), 2040 mg (group B) and 3060 mg (group C), in comparison with a placebo (group D). Arterial pressure, heart rate, ECG pattern and a complete blood analysis showed no change at any COP dosage, with the exception of blood phosphate, which increased in groups B and C. Cumulative urinary excretion of phosphate and creatinine and diuresis increased, whereas other urine parameters did not change. The phosphate and creatinine increases derived from the COP molecule and the increase in diuresis from a simple osmotic process required to dilute the phosphate in the tubular fluid. All these alterations were statistically significant and dose-related with COP and had been expected. COP proved to be a very well tolerated drug without any evident side effect.